Prostate Cancer Market Research Report – Forecast to 2023 Global Industry Survey, Growth, Competitive Landscape and Forecasts to 2023 CREATED BY Market Research Future (Part of Wantstats Research & Media Pvt. Ltd.)

Prostate Cancer Market Research Report – Forecast to 2023 Market Overview The global prostate cancer market is showing the steady growth; mainly owing to increase in patient population. According to report published by Centers for Disease Control and Prevention, in 2014, there were around 172,258 men in the United States, who diagnosed with prostate cancer and around 28,343 men died from prostate cancer. These rising number of prostate cancer create an opportunity for the player to introduce innovative treatment option. Companies are continuously invent new treatment to capture the global market. Thus players invest more in research and development activities. In this regards, Bayer Pharma AG announced that they have many drugs for the treatment of prostate cancer in there pipeline such as Radium-223 dichloride and BAY (ODM-201, AR antagonist). Browse Report

Segmentation : Product type and end-users are two segments that have been included by MRFR in their recent study of the global prostate cancer market. This segmentation takes the reader closer to factors and intake potentials for a better understanding of the growth curve of the market. Based on the product type, the global prostate cancer market can be segmented into targeted therapies, therapeutic vaccines, hormone therapy and others. The targeted therapy segment is expecting high growth during the forecast period. Based on the end-users, the prostate cancer market can be segmented into hospitals, clinics, and others. The hospitals segment is gaining better traction due to enhanced facilities for the treatment. Request a Sample Prostate Cancer Market Research Report – Forecast to 2023

Application & Major Players in this Research: Market Prominent Players: Some of the key players in this market are: OncoGenex Pharmaceuticals Inc. (US), Bayer Pharma AG (Berlin), Progenics Pharmaceuticals, Inc. (US), TOLMAR Inc. (US), OncBioMune Pharmaceuticals Inc. (US), Endo Pharmaceuticals Inc., Tokai Pharmaceuticals, Inc. and others. Commenting on the report, an analyst from Market Research Future (MRFR)’s team said: The competitive market is witnessing several strategies such as mergers and collaborations that could take the market forward. For instance, Illumina bought Edico Genome, a data analysis company that provides solutions for NGS. Myriad Genetics acquired Counsyl, a specialist in carrier screening and non-invasive prenatal screening. Get Prostate Cancer Market Research Report – Forecast to 2023

About Us: Market Research Future At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous- Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. For more information kindly visit or contact us at Copyright © 2018 Market Research Future All Rights Reserved. This document contains highly confidential information and is the sole property of Market Research Future. No part of it may be circulated, copied, quoted, or otherwise reproduced without the written approval of Market Research Future. Prostate Cancer Market Research Report – Forecast to 2023

MARKET RESEARCH FUTURE THANK YOU Ph: (US) Ph: (UK)